CJC-1295 + Ipamorelin

This stack pairs two peptides that push toward the same goal from two directions. CJC-1295 is a lab-made version of growth hormone releasing hormone (GHRH), the signal your brain uses to tell the pituitary to release growth hormone. Ipamorelin acts on the ghrelin receptor, a second switch for the same release. Instead of adding growth hormone from outside, the idea is to amplify your own natural pulses.

The "no DAC" detail matters. The original CJC-1295 carries a drug affinity complex (DAC) that lets it bind to blood proteins and last for days. The version most people mean in this stack has no DAC, so it acts for a much shorter time. Most of the published human data on CJC-1295, including a 2006 study in healthy adults in the Journal of Clinical Endocrinology and Metabolism that found sustained rises in growth hormone and IGF-1, used the DAC version.

Why it is popular: growth hormone and IGF-1 are central to body composition, muscle repair and recovery, so a stack built to boost your own release is a magnet for people chasing lean muscle and fat loss. Ipamorelin stands out because, in the 1998 study that introduced it, it released growth hormone without raising cortisol or ACTH, even at doses far above those needed for growth hormone release in animals, which made it look unusually selective.

What the research says: the combination has not been tested in a published trial. Ipamorelin reached a phase 2 trial for bowel recovery after surgery, where it was generally tolerated but did not significantly speed recovery compared with placebo. Neither peptide is FDA-approved. FDA lists ipamorelin in Category 2 for 503B compounding, and lists CJC-1295 as nominated but withdrawn while noting reported serious adverse events such as increased heart rate and a systemic vasodilatory reaction. Both are prohibited in sport by WADA. A clinician can tell you whether growth hormone testing makes sense for you.